In KRAS-mutated and BRAF wild-type metastatic CRC patients receiving a cetuximab- and irinotecan-based third-line therapy, increased expression of miR-let-7a correlated with improved OS and PFS. This evidence concerns the gene KRAS and colorectal carcinoma.